ASCO 2026 clinicians highlighted unmet needs from navigating complex treatment decisions and overcoming translation gaps, to optimizing regimens.
Alicia Morgans, MD, MPH
Advertisement
Articles by Alicia Morgans, MD, MPH
ARACOG trial data highlight cognitive effects of ARPIs in prostate cancer, showing less cognitive decline with darolutamide than enzalutamide, notes Alicia Morgans, MD, MPH.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
2
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently
3
5 Ongoing Clinical Trials in Myeloproliferative Neoplasms
4
Defunding Co-Payment Assistance Disrupted nAMD Care
5